RU2018136200A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2018136200A3 RU2018136200A3 RU2018136200A RU2018136200A RU2018136200A3 RU 2018136200 A3 RU2018136200 A3 RU 2018136200A3 RU 2018136200 A RU2018136200 A RU 2018136200A RU 2018136200 A RU2018136200 A RU 2018136200A RU 2018136200 A3 RU2018136200 A3 RU 2018136200A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662309330P | 2016-03-16 | 2016-03-16 | |
| US62/309,330 | 2016-03-16 | ||
| US201662416058P | 2016-11-01 | 2016-11-01 | |
| US62/416,058 | 2016-11-01 | ||
| PCT/US2017/022791 WO2017161174A1 (en) | 2016-03-16 | 2017-03-16 | Extended release conjugates of exenatide analogs |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2018136200A RU2018136200A (ru) | 2020-04-16 |
| RU2018136200A3 true RU2018136200A3 (OSRAM) | 2020-12-25 |
| RU2764547C2 RU2764547C2 (ru) | 2022-01-18 |
Family
ID=59852218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018136200A RU2764547C2 (ru) | 2016-03-16 | 2017-03-16 | Конъюгаты аналогов эксенатида с замедленным высвобождением |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20200164083A1 (OSRAM) |
| EP (2) | EP3922269A1 (OSRAM) |
| JP (1) | JP7017248B2 (OSRAM) |
| KR (1) | KR20180129825A (OSRAM) |
| CN (1) | CN109414469A (OSRAM) |
| AU (2) | AU2017234680A1 (OSRAM) |
| BR (1) | BR112018068639A2 (OSRAM) |
| CA (1) | CA3016814A1 (OSRAM) |
| MX (1) | MX2018011149A (OSRAM) |
| RU (1) | RU2764547C2 (OSRAM) |
| SG (1) | SG11201807832VA (OSRAM) |
| WO (1) | WO2017161174A1 (OSRAM) |
| ZA (2) | ZA201805953B (OSRAM) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10745456B2 (en) * | 2015-04-01 | 2020-08-18 | The Scripps Research Institute | Methods and compositions related to GPCR agonist polypeptides |
| JOP20190245A1 (ar) | 2017-04-20 | 2019-10-15 | Novartis Ag | أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط |
| AR116566A1 (es) | 2018-10-03 | 2021-05-19 | Novartis Ag | Administración sostenida de polipéptidos similares a la angiopoyetina 3 |
| EP3946460A4 (en) | 2019-04-05 | 2023-03-29 | Prolynx LLC | IMPROVED CONJUGATIONAL LINKERS |
| KR20220045975A (ko) * | 2019-08-07 | 2022-04-13 | 프로린크스 엘엘시 | 베타-제거 링커에 의해 가교된 하이드로겔의 증기 멸균 |
| JP2023550784A (ja) * | 2020-11-25 | 2023-12-05 | プロリンクス エルエルシー | C-ナトリウム利尿ペプチドの徐放性ヒドロゲルコンジュゲート |
| WO2025128916A1 (en) * | 2023-12-13 | 2025-06-19 | Cellanome, Inc. | Devices and methods for analyzing biological samples |
| KR102716759B1 (ko) | 2023-12-20 | 2024-10-15 | (주)인벤티지랩 | 엑세나타이드를 포함하는 서방형 주사제 조성물 및 이의 제조 방법 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0007823A8 (pt) * | 1999-01-14 | 2017-03-21 | Amylin Pharmaceuticals Inc | Métodos de supressão do glucagon |
| AU2003273300A1 (en) * | 2002-09-06 | 2004-03-29 | Bayer Pharmaceuticals Corporation | Modified glp-1 receptor agonists and their pharmacological methods of use |
| WO2004035623A2 (en) | 2002-10-02 | 2004-04-29 | Zealand Pharma A/S | Stabilized exendin-4 compounds |
| EP1845105A4 (en) * | 2005-01-14 | 2009-02-18 | Wuxi Grandchamp Pharmaceutical | MODIFIED EXENDINES AND CORRESPONDING USES |
| GB2427360A (en) | 2005-06-22 | 2006-12-27 | Complex Biosystems Gmbh | Aliphatic prodrug linker |
| CN102827284B (zh) * | 2006-11-14 | 2015-07-29 | 上海仁会生物制药股份有限公司 | 带有聚乙二醇基团的Exendin或其类似物及其制剂和用途 |
| WO2008116294A1 (en) | 2007-03-23 | 2008-10-02 | Matregen Corp. | Exendin analogs |
| WO2009158668A1 (en) | 2008-06-26 | 2009-12-30 | Prolynx Llc | Prodrugs and drug-macromolecule conjugates having controlled drug release rates |
| WO2010017215A2 (en) * | 2008-08-04 | 2010-02-11 | The Regents Of The University Of California | Biodegradable microspheres and methods of use thereof |
| CN102711804B (zh) * | 2009-11-13 | 2015-09-16 | 赛诺菲-安万特德国有限公司 | 包含glp-1激动剂和甲硫氨酸的药物组合物 |
| EP2571496A4 (en) | 2010-05-05 | 2016-03-30 | Prolynx Llc | CONTROLLED RELEASE OF MEDICINE FROM DENIMERS |
| US8946405B2 (en) * | 2010-05-05 | 2015-02-03 | Prolynx Llc | Controlled release from solid supports |
| DK2566335T3 (en) * | 2010-05-05 | 2016-10-03 | Prolynx Llc | Controlled release of active ingredients from macromolecular CONJUGATES |
| US8263554B2 (en) * | 2010-06-09 | 2012-09-11 | Amylin Pharmaceuticals, Inc. | Methods of using GLP-1 receptor agonists to treat pancreatitis |
| JP6158185B2 (ja) | 2011-09-07 | 2017-07-05 | プロリンクス エルエルシー | 生分解性架橋を有するヒドロゲル |
| EP2768856A4 (en) * | 2011-10-18 | 2015-05-27 | Prolynx Llc | PEG CONJUGATES OF EXENATIDE |
-
2017
- 2017-03-16 EP EP21189671.7A patent/EP3922269A1/en not_active Withdrawn
- 2017-03-16 EP EP17767565.9A patent/EP3429608A4/en not_active Withdrawn
- 2017-03-16 JP JP2018548652A patent/JP7017248B2/ja not_active Expired - Fee Related
- 2017-03-16 CN CN201780018057.6A patent/CN109414469A/zh active Pending
- 2017-03-16 KR KR1020187029780A patent/KR20180129825A/ko not_active Abandoned
- 2017-03-16 US US16/085,139 patent/US20200164083A1/en not_active Abandoned
- 2017-03-16 CA CA3016814A patent/CA3016814A1/en active Pending
- 2017-03-16 RU RU2018136200A patent/RU2764547C2/ru active
- 2017-03-16 WO PCT/US2017/022791 patent/WO2017161174A1/en not_active Ceased
- 2017-03-16 AU AU2017234680A patent/AU2017234680A1/en not_active Abandoned
- 2017-03-16 MX MX2018011149A patent/MX2018011149A/es unknown
- 2017-03-16 SG SG11201807832VA patent/SG11201807832VA/en unknown
- 2017-03-16 BR BR112018068639A patent/BR112018068639A2/pt not_active IP Right Cessation
-
2018
- 2018-09-05 ZA ZA201805953A patent/ZA201805953B/en unknown
-
2019
- 2019-09-02 ZA ZA2019/05787A patent/ZA201905787B/en unknown
-
2021
- 2021-09-17 AU AU2021232810A patent/AU2021232810A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20200164083A1 (en) | 2020-05-28 |
| BR112018068639A2 (pt) | 2019-07-30 |
| ZA201805953B (en) | 2019-11-27 |
| CA3016814A1 (en) | 2017-09-21 |
| EP3922269A1 (en) | 2021-12-15 |
| ZA201905787B (en) | 2021-03-31 |
| AU2017234680A2 (en) | 2018-12-13 |
| AU2017234680A1 (en) | 2018-10-11 |
| JP2019511497A (ja) | 2019-04-25 |
| SG11201807832VA (en) | 2018-10-30 |
| EP3429608A4 (en) | 2019-12-11 |
| EP3429608A1 (en) | 2019-01-23 |
| AU2021232810A1 (en) | 2021-10-14 |
| KR20180129825A (ko) | 2018-12-05 |
| WO2017161174A1 (en) | 2017-09-21 |
| JP7017248B2 (ja) | 2022-02-08 |
| RU2018136200A (ru) | 2020-04-16 |
| CN109414469A (zh) | 2019-03-01 |
| RU2764547C2 (ru) | 2022-01-18 |
| MX2018011149A (es) | 2019-05-30 |